and Alcohol Abuse , Bethesda , MD , USA Thyrotropin-releasing hormone (TRH), a neuromodulator and possibly a neurotransmitter in the central nervous system, was shown in a prior study of young normal volunteers to attenuate the memory impairment induced by the anticholinergic drug scopolamine. In the present study, the cognitive, behavioral and physiologic effects of high dose TRH (0.5 mg/kg), both alone and following administration of scopolamine, were examined in 10 Alzheimer's disease (AD) patients (mean age&plusmn;SD=63.5 years) and 12 older normal volunteers (mean age=64.9&plusmn;8.8 years). On the day AD subjects received TRH alone, modest but statistically significant improvement from baseline performance was documented on some tests of learning and memory, especially in those with mild dementia severity. In comparing cognitive test performance between the scopolamine alone and scopolamine+TRH conditions, only two test scores were significantly higher in the latter condition. In the group of older volunteers, TRH did not attenuate scopolamine-induced cognitive impairment, contrary to prior findings in a group of younger controls. In fact, older subjects performed worse after receiving scopolamine followed by TRH than after receiving scopolamine alone. In addition, no change from baseline cognitive performance was detected after subjects received TRH alone. These findings raise several questions and speculations on possible age-related changes in the cholinergic system, as well as on the mechanism of the interaction of TRH with the cholinergic system.
Introduction
The tripeptide thyrotropin-releasing hormone (TRH) has been proposed to have potential therapeutic value in Alzheimer's disease (AD) (Yarbrough, 1979; Metcalf, 1982) . This proposal arises from the fact that TRH and TRH analogs have been shown, in animal studies, to have positive neuromodulatory effects on the cholinergic system (Breese et al., 1975;  Yarbrough, 1979; Horita, Carino and Lai, 1986; Suzuki et al., 1989; Hutson, Semark and Middlemeiss, 1990; Okada, 1991) and to facilitate memory and learning in animal paradigms used to model the memory impairment of AD [e.g. after administration of the centrally active anticholinergic drug scopolamine (Yamazaki, Nagaoka and Nagawa, 1986; Yamamura et al., 1991) or lesions of the septohippocampal system (Horita et al., 1989; Yamamura et al., 1991) ]. In addition, areas of the brain thought to be involved in learning and memory, the amygdala, hippocampus and temporal cortex, have high concentrations of TRH receptors (Manaker et al., 1986) . It has been questioned, though, whether sufficient quantities of a peptide such as TRH could be delivered across the bloodbrain barrier to the brain (Metcalf, 1982) .
In a previous study, we administered intravenously high doses of TRH (0.5 mg/kg) to young normal volunteers and were able to demonstrate an attenuation of some of the cognitive impairment induced by the anticholinergic drug scopolamine (Molchan et al., 1990 ). The scopolamine model of geriatric memory dysfunction is widely employed experimentally (Drachman and Leavitt, 1974 ; Bartus et al., 1982; Sunderland et al., 1986) , and some pharmacological agents that reverse scopolamine-induced cognitive impairment have been shown to be of modest benefit to memory performance of elderly subjects as well as of some patients with AD (Drachman, 1977; Sitaram, Weingartner and Gillin, 1978; Mewaldt and Ghoneim, 1979 ; Mohs et al., 1985) .
Given our previous experience with TRH in young normals (Molchan et al., 1990) , and two prior studies in AD subjects using lower doses of TRH (Mellow et al., 1989; Lampe et al., 1990) , we sought to examine the cognitive, behavioral and physiologic effects of high dose TRH in a group of patients with AD and in older normal volunteers. In addition, we hoped to learn about the modulatory effects of TRH on responses to scopolamine in these subject groups.
Methods

Subjects
Ten AD patients (four females and six males; mean age + SD = 63.5 + 7.8 years) and 12 normal volunteers (three females and nine males; mean age + SD = 64.9 ± 8.8 years) participated in the study after informed consent and screening which excluded any medical or psychiatric illness (Table 1) . Probable AD was diagnosed according to ADRDA/NINCDS criteria (McKhann et al., 1984) . Dementia severity was assessed by staff members during the inpatient admission in which they participated in the protocol, using the Global Deterioration Scale (GDS) (Reisberg et al., 1982) . All subjects were drug-free for at least 3 weeks prior to the study. Normal volunteers were paid for their participation.
Experimental design
After the baseline cognitive battery, subjects participated in three study days, each (Safer and Allen, 1971) , and that central effects of high-dose TRH occur between 30 and 90 min after infusion (Mellow et al., 1989; Molchan et al., 1990) .
Behavioral ratings and digit span testing were performed by the physician investigator at four time points on each study day, prior to, and 30, 60 and 135 min after scopolamine/placebo administration.
Behavioral ratings included two visual analog scales (VAS), which range from 0 to 100 mm, and the NIMH behavioral rating scale (which ranges from 0 or 'not present' to 6 or 'very marked') and symptom checklist (which ranges from 0 or 'none' to 3 or 'much') (van Kammen and Murphy, 1975 (Metcalf, 1982) , and is quickly metabolized, having a plasma half-life of only 4-5 min (Bassiri and Utiger, 1973) . The dose of TRH was chosen based on results from previous studies in which cognitive effects were demonstrated using similar doses (Mellow et al., 1989; Molchan et al., 1990) . In addition, significantly elevated levels of CSF TRH have been documented 120 min after peripheral administration of high doses of the peptide (Mitsumoto et al., 1986) . TRH was purchased from Peninsula Laboratories (Belmont, CA) and analyzed for purity by the NIH Pharmaceutical Development Service.
The dose of scopolamine used in the AD group was chosen based on results from a prior study which showed that after 0.25 mg, side effects are tolerable such that cognitive testing can usually be completed, with a significant decline in cognitive performance demonstrated . In the normal volunteers, the dose was chosen based on a prior study of a range of scopolamine doses which showed that statistically significant decreases in cognitive test performance in older normal volunteers occur at the 0.5 mg dose .
Note that no placebo/placebo day was included in the study design, which was established primarily to compare performance among drug conditions. No statistically significant differences between performance on similar cognitive test batteries administered at baseline, prior to a subject's participation in drug studies, and cognitive performance during placebo conditions had been shown in 14 young normal volunteers (Sitaram, Weingartner and Gillin, 1978) and 11 AD patients by ANOVA. Retrospective analysis of variance (ANOVA) of data from another study, of 10 AD patients and 10 older controls, also showed no differences between baseline and placebo day cognitive performance. These data were collected in conjunction with a study examining the effects of a range of scopolamine doses in those subjects ; it was not included in that report but the data are available on request. In addition, no differences have been shown between tests of memory and information processing done prior to drug administration (time 0) and after administration of placebo (Wesnes and Warburton, 1984; Sunderland et al., 1987) . For Mellow et al., 1989) .
Cognitive tests
Subjects were administered a baseline cognitive battery that included the Wechsler Memory Scale (WMS) (Wechsler, 1945) and are summarized below.
Vigilance task
Subjects were read a list of 12 categorically related words, six of which were repeated; subjects were instructed to signal the examiner upon hearing a word for the second time as a measure of vigilance-attention. The number of correctly identified words that had been heard twice (a maximum of six words) was recorded as the score. Subjects were later asked to freely recall items from the list. Subjects were then read a list of 24 words, 12 of which were from a previously presented list (where six had been presented once and six had been presented twice), and 12 completely new words. Accuracy of the recognition of words that had been presented previously (either once or twice) was recorded as a measure of recognition memory. As words were recognized, subjects were asked to recall how frequently a word had been presented (once or twice). The difference between the mean reported frequency of the once-presented and twicepresented words was used as a measure of automatic memory processes (Hasher and Zacks, 1979) .
Category retrieval
As a measure of retrieval from knowledge memory, subjects were given two letters and asked to generate words beginning with those letters. They were then given words representing a broad category and asked to generate related words (Battig and Montague, 1969 (Buschke, 1973 (Yamazaki, Nagaoka and Nagowa, 1986; Horita et al., 1989; Mellow et al., 1989; Lampe et al., 1990; Molchan et al., 1990) . Two-tailed probabilities were used for the normal volunteer data. A binomial (signed rank) test was also performed to compare cognitive test scores after scopolamine and after scopolamine + TRH in the normals.
ANOVA was also used to check for carry-over or order effects of drug administration.
Behavioral data from the VAS were analyzed using repeated measures ANOVA to evaluate both of the within-subject variables of drug condition and time simultaneously, with a priori contrasts between study days. One-tailed probabilities were used to maximize detection of the described analeptic effect of TRH (Breese et al., 1975; Horita, Carino and Lai, 1986; Mellow et al., 1989) on measures of alertness, concentration and drowsiness. The maximum change from baseline values (Winer, 1982) .
Physiologic data were analyzed using one-way repeated measures ANOVA, and paired t-tests (two-tailed) Table 3 . No differences from baseline were detected on the day subjects received TRH alone (Table 3) . 
Discussion
In a prior study, we showed that TRH attenuated the cognitive impairment associated with scopolamine administration in young normal volunteers (Molchan et al., 1990 (Fig. 1) , indicating that the brains of these less impaired subjects were better able to respond to the intervention than the more severely demented patients.
TRH attenuated the cognitive effects of scopolamine only on a recognition memory test and backward digit span (Table 2a ). In the prior study of young normal volunteers, TRH attenuated the effects of scopolamine on a larger number of tests (Molchan et al., 1990) . Presumably, this would be due to the inability of already compromised cholinergic systems in the AD subjects to recover from the additional anticholinergic, cognitionimpairing effects of scopolamine.
The effects of TRH in older normal volunteers were somewhat anomalous, in that their cognitive performance decreased after the addition of TRH to scopolamine, with no change or a decrease from baseline scores after administration of high dose TRH alone (Table 2b ). This differs from findings in young normal volunteers and animal studies, in which TRH and TRH analogs attenuate scopolamine-induced cognitive impairment (Yamazaki, Nagaoka and Nagawa, 1986; Horita et al., 1989; Molchan et al., 1990; Yamamura et al., 1991 (Molchan et al., 1990) and cannot be explained by baseline differences, as baseline cognitive performance between the two groups was not significantly different, as assessed by t-tests (unpublished data). The cognitive findings in older volunteers also contrast with those of AD patients, though results from the two groups are not directly comparable as they received different doses of scopolamine.
The contrasting findings between the previous study in young normal volunteers (Molchan et al., 1990 ) and the present results in older normals raise several questions and speculations on possible differences in pathophysiologic changes which occur in the cholinergic system with age and in AD, as well as on the mechanisms of interaction between TRH and the cholinergic system in older, as compared with younger, subjects. The most consistently demonstrated findings in the cholinergic system that occur in the aged brain are decreased acetylcholine (ACh) synthesis (Gibson, Peterson and Jenden, 1981; Decker, 1987) , decreased ACh release (Decker, 1987; Wu et al., 1988) and decreased responsivity of cholinergic neurons to ACh (Bartus et al., 1982; Lippa et al., 1985; Decker, 1987) . Theories as to the mechanism by which TRH may interact with the cholinergic system to improve cognitive performance in scopolamine-treated young human subjects and animals, in animals with septo-hippocampal lesions and in patients with AD include: (1) an increase in the synthesis (Narumi et al., 1983) and/or release of ACh (Suzuki et al., 1989; Hutson, Semark and Middlemeiss, 1990; Okada, 1991) ; (2) an increase in ACh receptor sensitivity (Winokur and Beckman, 1978) (though this has not been observed by some investigators); and (3) direct excitation of cerebral cortical (Lamour, Dutar and Jobert, 1983 ) and septohippocampal neurons (Lamour et al., 1989) . A direct action of TRH at the cholinergic receptor has not been demonstrated. In that TRH has been shown to facilitate ACh release, and ACh availability and release may be impaired with ageing (Decker, 1987; Wu et al., 1988) , the most likely explanation for the differential effects of scopolamine + TRH in older and younger subjects may be decreased release of ACh by TRH in the older subjects.
An additional change shown to occur with age in several animal and human studies is that with increasing age there is a loss of muscarinic receptors in the cerebral cortex (White et al., 1977; Perry, 1980; Nordberg and Winblad, 1981; Rinne, 1987; Pedigo, 1988; Schwarz et al., 1990) . Some animal studies have shown that this loss is due primarily to a decrease in the density of type 1 muscarinic (M 1 ) receptors (Pedigo, 1988; Schwarz et al., 1990) . In contrast, in AD a decrease in the density of type 2 muscarinic (M2) receptors has been documented, with that of M1 receptors remaining relatively intact (Mash, Flynn and Potter, 1985; Araujo et al., 1988; Lange et al., 1990) .
Speculatively, our data may suggest that scopolamine, which blocks M receptors with significantly higher affinity than M2 receptors (Burke, 1986) , may therefore allow the autoregulatory pre-synaptic M2 receptors to decrease ACh release, especially in older normals who may have fewer M1 and relatively intact numbers of M2 receptors in the first place (Pedigo, 1988; Schwarz et al., 1990) . Possibly, because of this or other age-related changes, the facilitatory effect of TRH on the cholinergic system may not occur in normal older subjects as it apparently did in younger subjects (Molchan et al., 1990 (Brandeis et al., 1990) .
It should also be noted that alterations in other neurotransmitter systems that occur with age may impact on cholinergic system responsivity and on memory performance (Thompson et al., 1984; Zornetzer, 1986; Marcyniuk, Mann and Yates, 1989; Wenk et al., 1989) , and that TRH affects some of these systems, most notably the noradrenergic and dopaminergic (Metcalf, 1982; Horita, Carino and Lai, 1986 (Horita, Carino and Lai, 1986) , the rationale for the use of TRH for AD patients is strengthened, in view of the documented deficits in a number of neurotransmitter systems in this disease (Price, 1986; Zweig et al., 1988) .
The question of whether behavioral side effects may have influenced cognitive test performance after the administration of scopolamine and TRH recurs in every study that utilizes these agents. TRH has analeptic effects (Breese et al., 1975; Horita, Carino and Lai, 1986; Mellow et al., 1989) which could conceivably contribute to its attenuation of some of the effects of scopolamine, which usually causes some drowsiness. The analeptic effect does not seem to be a factor in the present study, as shown by the lack of significant change on the measure of vigilance-recognition, forward digit span and CPT in the normals (Table 2b) , which were used as measures of attention, and the lack of significant correlations between cognitive test scores and measures of drowsiness and alertness on the day subjects received TRH. Moreover, on the day subjects received TRH, there were no differences from baseline in alertness, drowsiness and other behavioral measures, nor were there significant differences on these parameters between the scopolamine and scopolamine + TRH conditions (Table 3 (Horita, Carino and Lai, 1986; Mattila and Bunag, 1986; Okuda, Mizobe and Miyazaki, 1987; Brezenoff, Vargas and Xiao, 1988 (Horita, Carino and Lai, 1986) . The mean temperature increase was greater on the day subjects received TRH alone ( Fig. 1) (Mellow et al., 1989) and high dose TRH (up to 12 mg i.v.) in combination with lecithin (Lampe et al., 1990) . These results suggest that further studies with TRH and TRH analogs, which are much more biologically stable than the native peptide as well as more accessible and specific to the central nervous system (Griffiths et al., 1989) , may be warranted in patients with this illness. TRH analogs too, have been shown, in animal studies, to facilitate impaired memory performance to a greater degree than TRH itself (Yamazaki, Nagaoka and Nagawa, 1986; Yamamura et al., 1991) . Also, like many peptides, TRH has been shown to exhibit trophic activity in the nervous system (Faden, Jacobs and Smith, 1984; Behbehani et al., 1990) , and it has been hypothesized that trophic factors may be of benefit to patients with AD (Hefti, Dravid and Hartikka, 1984: Price, 1986) .
Results in older volunteers in the present study were contrary to findings in a group of young controls, in whom an attenuation of scopolamine-induced cognitive impairment occurred after TRH administration, presumably by facilitating cholinergic system function (Molchan et al., 1990) . These contrasting results suggest that the changes that occur in the brain with age, whether in receptor density, receptor sensitivity, second messenger systems or through some other mechanism, may change the response to this neuropeptide. The cognitive and physiologic responses reported in this study also differed from those reported in age-matched AD subjects and imply that some of the changes in neurochemical systems and mechanisms involved in the cognitive impairment which occur in normal ageing and in AD may be different. This remains a topic of some controversy (Whitehouse and Au, 1986; Decker, 1987 
